The FDA's cancer-drugs advisory panel is scheduled to meet Thursday to consider regulatory action on the use of Johnson & Johnson's and Amgen's anemia drugs, which have been linked in certain cancer patients to faster tumor development, shortened survival and higher blood-clot risk. The agency is considering nullifying the approval of the drugs -- marketed as Procrit by J&J and Epogen and Aranesp by Amgen -- for use in cancer patients.

Related Summaries